Does Rallies show 13F holders for BDTX?

Yes. Rallies tracks hedge fund and 13F ownership data for BDTX, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BDTX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BDTX. It does not provide personalized investment advice.

BDTX (Black Diamond Therapeutics, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings

Black Diamond Therapeutics, Inc. Common Stock (BDTX) is a publicly traded Healthcare sector company. As of May 21, 2026, BDTX trades at $3.66 with a market cap of $147.84M and a P/E ratio of 8.81. BDTX moved +20.00% today. Year to date, BDTX is +40.08%; over the trailing twelve months it is +65.90%. Its 52-week range spans $1.20 to $4.94. Analyst consensus is strong buy with an average price target of $10.25. Rallies surfaces BDTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BDTX stock?

Hedge funds tracked by Rallies that own BDTX include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Black Diamond Therapeutics, Inc. Common Stock.

BDTX Key Metrics

Key financial metrics for BDTX
Metric	Value
Price	$3.66
Market Cap	$147.84M
P/E Ratio	8.81
EPS	$0.39
Dividend Yield	0.00%
52-Week High	$4.94
52-Week Low	$1.20
Volume	3.11K
Avg Volume	0
Revenue (TTM)	$70.00M
Net Income	$22.37M
Gross Margin	0.00%

Top Hedge Funds Holding BDTX

Exoduspoint Capital holds 872.68K shares of BDTX, changed +48.26% as of Sep 30, 2024.

Latest BDTX News

Black Diamond Reports $9M Q1 Loss, $118M Cash and First EGFRvIII+ GBM Patient Dosed — May 7, 2026
Black Diamond Ends 2025 with $128.7M Cash, Sets Q2 2026 Phase 2 NSCLC and GBM Trials — Mar 16, 2026
Black Diamond to Present NSCLC PFS Data After 60% ORR, 93% DCR — Mar 6, 2026

Recent BDTX Insider Trades

BIOTECH GROWTH N V sold 1.00M (~$2.07M) on Mar 19, 2025.
BIOTECH GROWTH N V sold 300.00K (~$582.90K) on Mar 19, 2025.
BIOTECH GROWTH N V sold 1.00M (~$2.31M) on Mar 19, 2025.

BDTX Analyst Consensus

5 analysts cover BDTX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.25.

Common questions about BDTX

Who owns BDTX stock?: Hedge funds tracked by Rallies that own BDTX include Exoduspoint Capital. The latest tracked quarter is Sep 30, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Black Diamond Therapeutics, Inc. Common Stock.
Does Rallies show 13F holders for BDTX?: Yes. Rallies tracks hedge fund and 13F ownership data for BDTX, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BDTX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BDTX. It does not provide personalized investment advice.